Liposomes: From the bench to the bed
Liposomes: From the bench to the bed
复制标题
DOI:
10.1081/lpr-120017488
复制
发表时间:
2003-01-01
影响因子:
4.4
通讯作者:
Storm, G
中科院分区:
文献类型:
--
作者:
Crommelin, DJA;Storm, G
Several liposomal formulations have been successfully developed and reached the market place. Examples are doxorubicin, daunorubicin, and amphothericin containing liposomes. A number of other liposomal products are presently under development both for parenteral and non-parenteral use. All these formulations have to meet the high quality criteria as defined for pharmaceutical products. To ensure proper liposome performance, batch to batch reproducibility, and stability of the liposome dispersions has to be established. This requires definition of the charactistics of liposome dispersions in the preformulation stage, clinical test stage, and final production stage.Barenholz and Crommelin (1) listed quality control assays for liposomal preparation (Table 1). This list is a comprehensive list and the selection of relevant assays depends on the stage of development of the liposome product. Interestingly, the FDA is presently working on guidelines for liposome products and some issues brought up in these guidelines will be discussed. When one goes through Table 1, it is clear that the physical and chemical characterization of liposomes is complex. In particular, in these dispersions physical properties such as liposome size and lamellarity are often heterogeneous in nature and difficult to grasp in one parameter. Another issue of debate is setting the specifications for the liposomes formulations. What is acceptable in terms of compound and product related impurities?